#EBITDA #GROWTH

In FY23, EBITDA was ₹2,050 cr, a decline of 6% YoY.In 9M FY24, EBITDA was ₹1,751 cr, a growth of 12% YOY. The company remains focused on expanding and investing aggressively in its digital platform, thereby restricting the operational performance, in the near term.

5 Year CAGR: 20.9%

#PAT #GROWTH

In FY23, PAT was ₹888 cr, a decline of 19% YoY. This was due to exceptional gain of ₹294 cr in Q1 FY22. PAT growth was also impacted by lower operating profit.In 9M FY24, PAT was ₹668 cr, a decline of10% YoY. Profit during the period was impacted mainly due to higher finance and tax costs. the pick up in primary and secondary patient care, elective surgeries, addition of laboratories & collection centers in the diagnostic business coupled with focus on private label sales is likely to drive earnings growth.

#EBITDA #MARGIN

In FY23, EBITDA margin was 12.34%, a contraction of a 256 bps YoY. In 9M FY24, EBITDA margin was 12.4%, a contraction of 28 bps YoY. The margin was impacted due to the reduced share of elective and surgical revenue in the revenue mix due to the holiday and festive season, as well as investments in clinical talent, which is yet to be fully optimized.further increasing occupancy rate, payor mix, case mix and cost optimisation efforts are likely to aid in margin growth. However, this may be partially offset by the increased investment in Apollo 24/7 coupled with non cash expense arising out of ESOP charge which will continue for the next three years.

#PAT #MARGIN

In FY23, PAT margin was 5.34%, a contraction of 217 bps YoY due to exceptional gain in base year.In 9M FY24, PAT margin was 4.73%, a contraction of 133 bps YoY.

#ROCE

In FY23, ROCE was 17.78%. The moderation in operating profitability had a bearing on the metric.

#ROE

Apolo Hospitals Enterprise Ltd. ROE was 15.16%. This moderation can be attributed to a higher base from the previous year, which was supported by exceptional gain of ₹294 cr

#DEBT #TO #EQUITY

Recently the debt to equity ratio was 0.44x.As on 30th September 2023, total debt stood at ₹3,010 cr. Out of which, long term debt stood at ₹2,016 cr.

#Management #Outlook

Apollo Health Co will leverage Keimed's vast network of more than 70,000 stores to accelerate its ₹1,500 cr private label portfolio. The combined entity is likely to generate revenue of ₹25,000 cr in 3 years with 7%-8% of EBITDA margin.

Apollo Hospitals 5450-5750
Expected level 6700
Support 5000

Companies Manufacture Drones in India

I) Government-Owned Giants

1️⃣ HAL

II) Military Drone Leaders

1️⃣ L&T
2️⃣ Zen Technologies
3️⃣ DCM Shriram

III) Commercial Drone Service Providers

1️⃣ Info Edge
2️⃣ Drone Destination
3️⃣ Droneacharya
4️⃣ Rattanindia Enterprises

IV) Drone Technologies

1️⃣ Paras Defence
2️⃣ Bharat Forge

Good morning

Gravita has 19% Market share in lead recycling in India.

• One of the largest recycling companies in India with global operations

• Presence in couple of verticals
- Lead
- Aluminium
- Plastic
- Rubber
- Turnkey solutions

Good morning

BIGGEST INTRADAY FALL IN NIFTY

May 2004:-18.33%

Oct 2012: -15.54%

Jan 2008:-14.59%

Oct 2008:-14.20%

March 2020:-13.30%

Oct 2008: -12.81%

Jan 2008:-12.76%

April 1992:-11.72%

May 1992:-11%

May 2006: -10.80%

Good morning